Literature DB >> 11798471

Characterization of the antitumor activities of IFN-alpha8 on renal cell carcinoma cells in vitro.

Y Yanai1, S Horie, K Yamamoto, H Yamauchi, H Ikegami, M Kurimoto, T Kitamura.   

Abstract

Interferon-alpha (IFN-alpha) has a number of therapeutic applications in the treatment of various human cancers and diseases of viral origin. IFN-alpha includes several subtypes, and little has been reported on the biologic properties of the individual subtypes. Here, we report on the individual antitumor effects of five IFN-alpha subtypes, alpha1, alpha2, alpha5, alpha8, and alpha10, against six renal cell carcinoma (RCC) cell lines in vitro. Among the subtypes, IFN-alpha8 most potently inhibited cell proliferation and delayed the G(1)/S transition. Synergistic induction of apoptosis was shown in two of the RCC cell lines when treated with the combination of IFN-alpha and IFN-gamma rather than with either IFN-alpha or IFN-gamma alone. IFN-alpha8 was most effective in the induction of apoptosis when combined with IFN-gamma. In addition, IFN-alpha8 had the strongest ability to upregulate HLA class II antigen expression in the subtypes examined. These data indicate that subtypes of IFN-alpha have disparate antitumor effects in vitro, and in vitro distinctions among the IFN-alpha subtypes should be appreciated more in clinical application.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11798471     DOI: 10.1089/107999001317205268

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  3 in total

1.  Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders.

Authors:  Toshio Ariyasu; Takeshi Tanaka; Noboru Fujioka; Yoshiaki Yanai; Shigeto Yamamoto; Hiroshi Yamauchi; Hakuo Ikegami; Masao Ikeda; Masashi Kurimoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 Jan-Feb       Impact factor: 2.416

2.  Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes.

Authors:  Sotaro Miwa; Yoshifumi Kadono; Toshiaki Sugata; Atsushi Mizokami; Mikio Namiki
Journal:  Int J Clin Oncol       Date:  2010-02       Impact factor: 3.402

3.  Interferon-α enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity.

Authors:  Xiao Han; Donghao Shang; Tiandong Han; Xiuhong Xu; Ye Tian
Journal:  Exp Ther Med       Date:  2014-04-25       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.